Pfizer today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the ...

GoodRx (GDRX) announced that it has become a major integration partner for Pfizer (PFE) and other pharmaceutical companies, ...

One panelist accused the F.D.A. of withholding data on potential harms. The advisers also are reviewing research on vaccines ...

The U.S. FDA has accepted and granted Priority Review for Pfizer’s supplemental Biologics License Application (sBLA) for HYMPAVZI.

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

Pfizer Inc. (NYSE: PFE)today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026 Adaptive Biotechnologies ...

Pfizer (PFE) stock in focus as Priovant, a partnership between the company and Roivant Sciences (ROIV) posts positive trial ...

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® ...